Dexmedetomidine Versus Propofol for Sedation During Awake Endotracheal Intubation

• Status: Not yet recruiting
• Trial end date: 2021-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the sedation effect of dexmedetomidine and propofol when they are both combined with midazolam and remifentanil during awake endotracheal intubation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
• Treatments: Dexmedetomidine; Midazolam; Propofol; Remifentanil

Criteria

Inclusion Criteria:

1. Age 18-65 Years old;

2. scheduled for elective surgery under general anesthesia with oral tracheal intubation;

3. The American Society of Anesthesiologists(ASA) grade is I or II, and the cardiac function is 1-2;

4. Body mass index (BMI) 18-30 kg/m2.

Exclusion Criteria:

1. Patients have severe cardiac diseases (cardiac function grading greater than grade 3/arrhythmia including sick sinus syndrome, atrial fibrillation, atrial flutter, atrioventricular block, frequent ventricular premature, multiple ventricular premature, ventricular premature R on T, ventricular fibrillation and ventricular flutter/acute coronary syndrome) or respiratory failure or hepatic failure or renal failure;

2. body mass index (BMI) ≥30 kg/m2 or <18 kg/m2;

3. Patients with poor blood pressure control (receive regular antihypertensive medical treatment but still have systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 90 mmHg);

4. Patients with a higher risk of reflux and aspiration, such as full stomach, gastrointestinal obstruction, gastroparesis, and pregnant women;

5. Patients have schizophrenia, epilepsy, Parkinson's disease, intellectual disability, hearing impairment.;

6. Patients who take sedative and analgesic drugs for a long time;

7. Patients who are allergic to propofol, dexmedetomidine, midazolam or remifentanil

8. Patients who are expected to be difficult to intubate;

9. Patients who are participating in other clinical trials, or who refuse to sign informed consent.